Vertex Pharmaceutica
VRTX
Delayed Nasdaq - 10/23 10:00:00 pm
151.06USD
-2.31%
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Discovers and develops novel, small molecule pharmaceuticals

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases.

It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis.

The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Number of employees : 2 150 persons.
Sales per Businesses
20152016
USD
(in Million)
%USD
(in Million)
%
KALYDECO631.6761.2%703.4341.3%
ORKAMBI350.6634%979.5957.5%
INCIVEK17.991.7%0.6100%
Sales per Regions
20152016
USD
(in Million)
%USD
(in Million)
%
United States763.3273.9%1,32277.7%
Europe219.6021.3%320.4618.8%
Other49.424.8%59.913.5%
United Kingdom----
Shareholders
- T. Rowe Price Associates, Inc.10.6%
- Fidelity Management & Research Co.6.92%
- The Vanguard Group, Inc.6.85%
- Wellington Management Co. LLP6.29%
- Capital Research & Management Co. (World Investors)6.11%
- BlackRock Fund Advisors5.20%
Managers
- Chairman, President & Chief Executive Officer :
    Jeff Leiden
- Chief Operating Officer & Executive Vice President :
    Ian Smith
- Chief Financial Officer & Senior Vice President :
    Thomas Graney
- Chief Medical Officer & Executive Vice President :
    Jeffrey Chodakewitz
- Chief Scientific Officer & EVP-Global Research :
    David Altshuler
- Senior VP-Clinical Development & Medical Affairs :
    Reshma Kewalramani
- Lead Independent Director :
    Bruce Sachs
- Lead Independent Director :
    Elaine Ullian
- Independent Director :
    Margaret McGlynn
- Independent Director :
    Terrence Kearney
Company contact information
50 avenue Northern
US-MA 02110 Boston, Massachusetts
États-Unis (les)

Phone : +1 617 444 6100
Fax : +1 617 444 6680
Internet : http://www.vpharm.com
Markets and indexes
- NASDAQ All Markets
- Nasdaq Global Select Market
- Nasdaq 100 / SP500
Stock Exchange Codes
- ISIN Code :  US92532F1003
- Bloomberg Code :  VRTX:US
- Reuters Code :  VRTX.O
Overall rating
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision